
|Articles|August 15, 2003
Iridex leads the way with retinal innovation; eyes cataract and glaucoma markets
In the ophthalmic market, there is a distinctive gap between industry leaders and followers.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Optigo Biotherapeutics names Andreas Wallnöfer, PhD, MBA, to board as lead retinal program advances
5


















































.png)


